Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer

被引：0
|
作者：
Trarbach, T. [1 ,2 ]
Schuette, K. [1 ,2 ]
Stoehlmacher, J. [1 ,2 ]
Goekkurt, E. [1 ,2 ]
Guenther, H. [1 ,2 ]
Ubbelohde, U. [1 ,2 ]
Stroszczynski, C. [1 ,2 ]
Ehninger, G. [1 ,2 ]
Folprecht, G. [1 ,2 ]
机构：
[1] W German Canc Ctr, Essen, Germany
[2] Univ Hosp Carl Gustav Carus, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15025
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] FIRST LINE CHEMOTHERAPY (FLC) USING OXALIPLATIN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFOX-4) COMBINED WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Man, S.
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 66 - 66
  • [34] Weekly administration of 5-fluorouracil (5-FU), folinic acid (FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) [FUFOXIRI] for patients with metastatic gastric or colorectal cancer
    Harba, A
    Peinert, S
    Grothe, W
    Jordan, K
    Kegel, T
    Mueller, LP
    Behrens, R
    Grothey, A
    Arnold, D
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 300S - 300S
  • [35] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.
    Smith, D. M.
    Legoux, J.
    Brunet, R.
    Adhoute, X.
    Blanc, J.
    Fonck, M.
    Vendrely, V.
    Becouarn, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [36] Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase VIIa study.
    Folrecht, G
    Lutz, MP
    Seufferlein, T
    Schoeffski, P
    Nolting, A
    Pollert, P
    Koehne, CH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 281S - 281S
  • [37] Adding weekly irinotecan to high-dose fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer - a phase II study
    Hofheinz, R
    Hartung, G
    Samel, S
    Emig, M
    Pilz, L
    Willeke, F
    Hochhaus, A
    Hehlmann, R
    Queisser, W
    ANTI-CANCER DRUGS, 2002, 13 (10) : 999 - 1004
  • [38] Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer
    Itabashi, Michio
    Tani, Kimitaka
    Muro, Kei
    Masuishi, Toshiki
    Ohashi, Yasuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [40] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
12345